Asia

DCGI asks Serum Institute to revise protocol for phase 2, 3 trials of Oxford COVID-19 vaccine

NEW DELHI: A CDSCO expert panel has sought clarifications from Serum Institute of India (SII) over its application to the Drugs Controller General of India (DCGI) seeking permission for conducting phase 2 and 3 human clinical trials of the Oxford vaccine candidate for COVID-19, official sources said on Wednesday.
The Subject Expert Committee (SEC) on COVID-19 which held its meeting on Tuesday deliberated on the application by SII and asked the Pune-based firm to revise its protocol for the phase 2 and 3 clinical trials, besides seeking some additional information.
On Wednesday evening, SII submitted a revised protocol for conducting the trials to the DCGI.
"The company on Tuesday was asked to clearly define phase 2 and phase 3 part of the protocol and resubmit their application for evaluation by the SEC," an official source said.
The panel also recommended that the proposed clinical trial sites be distributed across India, the source said.
"They also have not given justification for the proposed enrolment of 1,600 subjects during the trial," the source added.
Additional Director, Government Affairs, SII, Prakash Kumar Singh said, "We have submitted our revised protocol to DCGI office today evening for further action by SEC and DCGI."
The SII which has partnered with AstraZeneca for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its application to the DCGI on Friday, seeking permission for conducting the phase 2 and 3 trials of the potential vaccine 'Covidshield'.
"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of 'Covishield' in healthy Indian adults. The firm said that an around 1,600 participants of more than 18 years would be enrolled in the study," a source had said.
Initial results of the first two-phase trials of the vaccine conducted in five trial sites in the UK showed it has an acceptable safety profile and homologous boosting increased antibody responses, the source said.
To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed bRead More – Source

[contf]
[contfnew]

times of india

[contfnewc]
[contfnewc]

Related Articles

Asia

Joshua Wong and fellow activists plead guilty in Hong Kong protests trial

bbc– Hong Kong democracy activist Joshua Wong and two fellow campaigners are...

Asia

Works worth Rs 1,559 cr completed in Bihar out of PM s package of Rs 1.25 lakh cr: Congress

PATNA: Congress general secretary Randeep Surjewala on Tuesday claimed that works worth...

Asia

Ex-Trump fundraiser pleads guilty to illicit lobbying on 1MDB, China

WASHINGTON: A former top fundraiser for President Donald Trump pleaded guilty Tuesday...

Asia

Covid: Delhi more “open” than Mumbai

NEW DELHI: With Unlock 5.0 underway from October 15, more businesses and...